Business
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Mee
About this update from Enovis Corporation
[{"type":"image","alt":"Enovis Corporation","displaySize":"","headline":null,"caption":"Enovis Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qc6jvQoTNwKdaM8z5d_s_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Damien McDonald appointed CEO, effective as of May 12, 2025","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Company reiterates guidance for first quarter revenues and aEBITDA","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":125,"olType":false},{"type":"text","content":"WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.","length":755,"tagName":"p"},{"type":"text","content":"Sharon Wienbar, Lead Independent Director at Enovis, stated, “On behalf of the Board, I am thrilled to welcome Damien to the Enovis team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed highly qualified candidates and Damien stood out. His strong track record as CEO of a public, global medical technology combined with his long history of relevant business successes and his similar approach to business processes and culture make him the right leader for Enovis at this stage in our growth journey.”","length":581,"tagName":"p"},{"type":"text","content":"Mr. McDonald joins Enovis with more than 35 years of...